(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 April 2015 (23.04.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/055801 A1

(51) **International Patent Classification**:
C07K 14/605 (2006.01) *A61K 38/26* (2006.01)

(21) **International Application Number**:
PCT/EP2014/072293

(22) **International Filing Date**:
17 October 2014 (17.10.2014)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/892,256 17 October 2013 (17.10.2013) US

(71) **Applicants**: **ZEALAND PHARMA A/S** [DK/DK]; Smedeland 36, DK-2600 Glostrup (DK). **BOEHRINGER INGELHEIM INTERNATIONAL GMBH** [DE/DE]; Binger Strasse 173, 55216 Ingelheim am Rhein (DE).

(72) **Inventors**: **RIBER, Ditte**; Zealand Pharma A/S, Smedeland 36, DK - 2600 Glostrup (DK). **TOLBORG, Jakob Lind**; Zealand Pharma A/S, Smedeland 36, DK - 2600 Glostrup (DK). **HAMPRECHT, Dieter Wolfgang**; Boehringer Ingelheim GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). **RIST, Wolfgang**; Boehringer Ingelheim GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein (DE).

(74) **Agents**: **FORREST, Graham** et al.; Mewburn Ellis LLP, 33 Gutter Lane, London Greater London EC2V 8AS (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2015/055801 A1

(54) **Title**: ACYLATED GLUCAGON ANALOGUES

(57) **Abstract**: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.